Business opportunities

Héma-Québec acknowledges that intellectual property developed by its staff constitutes a valuable asset to its mission and considers as its responsibility that this intellectual property be exploited in an optimal fashion to the benefit of all Quebecers.

Our Patent Portfolio

Since its inception, Héma-Québec has patented five technologies developed in its research and development laboratories:

Description
This invention describes a method for high-yield, low-cost production of proteins by transgenesis in alfalfa plants.

Countries/Territories
(click on the desired country or territory for a copy of the patent or application)

Canada
United States of America
Australia
Austria
Denmark
Portugal
Spain
Germany
China
Japan
Israel
New Zealand

To learn more

Description

Interferon-alpha designates a family of proteins with antiviral and immunomodulatory properties of clinical significance. This technology allows to improve the yield of interferon-alpha produced in vitro from hematopoietic stem cells grown in culture.

Countries/Territories
(click on the desired country or territory for a copy of the patent or application)

United States of America
Europe

To learn more

Description
This patent describes a method for the separation of therapeutic immunoglobulins into a fraction that is enriched in autoantibodies reacting against serum proteins, and a second fraction that is depleted of autoantibodies specific to serum proteins. Serum-specific autoantibodies are able to form immune complexes with serum proteins. The immunomodulatory properties of these complexes could lead to clinical applications. The fraction that is depleted of autoantibodies is particularly well-suited for the treatment of immunoglobulin deficiency patients.

Countries/Territories
(click on the desired country or territory for a copy of the patent or application)

Austria
Germany
France
Ireland

To learn more

 

Description

This invention improves the in vitro expansion of hematopoietic stem cells, as well as the in vitro differentiation of these cells into blood platelet-producing cells. This technology is of clinical relevance, specially in the design of therapies involving hematopoietic stem cell transplantation

Countries/Territories
(click on the desired country or territory for a copy of the patent or application)

United States of America
Canada
Europe (pending)

To learn more

Description
This invention claims a method allowing long-term in vitro expansion of memory B lymphocytes, as well as the production of polyclonal immunoglobulins. This technology could be a valuable asset in the development of novel methods of in vitro antibody production.

Countries/Territories
International application filed in accordance with the PCT (Patent Cooperation Treaty) system

To learn more 

Are you interested in one of our technologies?

Héma-Québec seeks to develop its patented technologies and other intellectual properties, preferentially through licensing agreements.

Collaborations and partnerships

Héma-Québec is also willing to reach collaboration and partnership agreements with third parties interested in our technologies and our expertise. Examples of such agreements include:

  • research collaboration agreements;
  • biological material transfer agreements;
  • service agreements;
  • research contract agreements.

For more information, please contact:

Anne-Marie Larose, Ph.D., M.B.A.
Director of Business Development
Héma-Québec
4045 Côte-Vertu Blvd.
Saint-Laurent (Québec)  H4R 2W7 
Telephone: 514-832-5000 or toll-free 1-888-666-4362, ext. 6150
Fax: 514-832-1025